PORTFOLIO NEWS Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress May 8, 2023 Read More » NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data May 4, 2023 Read More » Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting May 3, 2023 Read More » Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201 May 2, 2023 Read More » Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting April 24, 2023 Read More » Circle Pharma’s First-in-Class Orally Bioavailable Macrocyclic Cyclin A/B Inhibitors Highlighted in Poster Presentations at American Association for Cancer Research Annual Meeting April 19, 2023 Read More » ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting April 18, 2023 Read More » Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations April 17, 2023 Read More » o Accent Presentation: “Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer” (AACR 2023) April 16, 2023 Read More » Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 April 16, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress May 8, 2023 Read More »
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data May 4, 2023 Read More »
Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting May 3, 2023 Read More »
Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting April 24, 2023 Read More »
Circle Pharma’s First-in-Class Orally Bioavailable Macrocyclic Cyclin A/B Inhibitors Highlighted in Poster Presentations at American Association for Cancer Research Annual Meeting April 19, 2023 Read More »
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting April 18, 2023 Read More »
Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations April 17, 2023 Read More »
o Accent Presentation: “Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer” (AACR 2023) April 16, 2023 Read More »
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 April 16, 2023 Read More »
